Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Sponsor: Otsuka America Pharmaceutical
A PHASE3 clinical study on Body Weight Change and Psychotic Disorder, this trial is completed. The trial is conducted by Otsuka America Pharmaceutical and has accumulated 7 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka America Pharmaceutical
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anaheim, United States, Augusta, United States, Austin, United States, Belo Horizonte, Brazil, Birmingham, United Kingdom, Botucatu, Brazil, Brooklyn, United States, Cerritos, United States, Dallas, United States, DeSoto, United States and 22 more location s